Ticagrelor Removal From Human Blood

JACC: Basic to Translational Science

Volumn 2, Issue 2, 2017, Pages 135-145

  Angheloiu, George O ^a,b,c   Gugiu, Gabriel B ^d   Ruse, Cristian ^e   Pandey, Rishikesh ^a   Dasari, Ramachandra R ^a   Whatling, Carl ^f  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UPMC Susquehanna   (United States)

^c The Heart Group   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e NEW ENGLAND BIOLABS   (United States)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

concentration; drug; P2Y12; platelet; removal; sorbent; ticagrelor

Indexed keywords

EID: 85018842758     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2017.01.007     Document Type: Article

References (25)

1. 1 Wallentin, L., Becker, R.C., Budaj, A., et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
2. 2 Ebrahimi, R., Dyke, C., Mehran, R., et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 53 (2009), 1965–1972.
3. 3 Held, C., Asenblad, N., Bassand, J.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57 (2011), 672–684.
4. 4 Cheng, V.E., Oppermen, A., Natarajan, D., Haikerwal, D., Pereira, J., Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor. Heart Lung Circ 23 (2014), e115–e117.
5. 5 Whitmore, T.J., O'Shea, J.P., Starac, D., Edwards, M.D., Waterer, G.W., A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy. Chest 145 (2014), 639–641.
6. 6 Chernoguz, A., Telem, D.A., Chu, E., Ozao-Choy, J., Tammaro, Y., Divino, C.M., Cessation of clopidogrel before major abdominal procedures. Arch Surg 146 (2011), 334–339.
7. 7 Fitchett, D., Mazer, C.D., Eikelboom, J., Verma, S., Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. Can J Cardiol, 29, 2013, 10427.
8. 8 Ganesan, S., Williams, C., Maslen, C.L., Cherala, G., Clopidogrel variability: role of plasma protein binding alterations. Br J Clin Pharmacol 75 (2013), 1468–1477.
9. 9 Ghahramani, P., Rowland-Yeo, K., Yeo, W.W., Jackson, P.R., Ramsay, L.E., Protein binding of aspirin and salicylate measured by in vivo ultrafiltration. Clin Pharmacol Ther 63 (1998), 285–295.
10. 10 Angheloiu, G.O., Hänscheid, H., Reiners, C., Anderson, W.D., Kellum, J.A., In vitro catheter and sorbent-based method for clearance of radiocontrast material during cerebral interventions. Cardiovasc Revasc Med 14 (2013), 207–212.
11. 11 Angheloiu, G.O., Hänscheid, H., Wen, X., Capponi, V., Anderson, W.D., Kellum, J.A., Experimental first-pass method for testing and comparing sorbent polymers used in the clearance of iodine contrast materials. Blood Purif 34 (2012), 34–39.
12. 12 Storey, R.F., Husted, S., Harrington, R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007), 1852–1856.
13. 13 Schwanke, U., Schrader, L., Moog, R., Storage of neutrophil granulocytes (PMNs) in additive solution or in autologous plasma for 72 h. Transfus Med 15 (2005), 223–231.
14. 14 Bonaca, M.P., Bhatt, D.L., Cohen, M., et al., for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
15. 15 Armstrong, D., Summers, C., Ewart, L., Nylander, S., Sidaway, J.E., van Giezen, J.J., Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 19 (2014), 209–219.
16. 16 Cattaneo, M., Schulz, R., Nylander, S., Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63 (2014), 2503–2509.
17. 17 Teng, R., Oliver, S., Hayes, M.A., Butler, K., Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38 (2010), 1514–1521.
18. 18 Department of Health and Human Services, Public Health Service Food and Drug Administration Center for Drug Evaluation and Research. Pharmacology/Toxicology Review and Evaluation. NDA Number: 22-433. Center Receipt Date January 29, 2010. Product: Brilinta (ticagrelor). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000PharmR.pdf. Accessed March 2017.
19. 19 Buchanan, A., Newton, P., Pehrsson, S., et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood 125 (2015), 3484–3490.
20. 20 Angheloiu GO, van Ryn J, Goss AM. Removal of dabigatran using sorbent hemadsorption. Paper presented at: the Scientific Sessions of American Heart Association; November 7-11, 2015; Orlando, Florida.
21. 21 Castellanos, M., Xifra, G., Fernández-Real, J.M., Sánchez, J.M., Breath gas concentrations mirror exposure to sevoflurane and isopropyl alcohol in hospital environments in non-occupational conditions. J Breath Res, 10, 2016, 016001.
22. 22 Träger, K., Fritzler, D., Fischer, G., et al. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs 39 (2016), 141–146.
23. 23 Jeyachandran, Y.L., Mielczarski, E., Rai, B., Mielczarski, J.A., Quantitative and qualitative evaluation of adsorption/desorption of bovine serum albumin on hydrophilic and hydrophobic surfaces. Langmuir 25 (2009), 11614–11620.
24. 24 Nylander, S., Schulz, R., Effects of P2Y12 receptor antagonists beyond platelet inhibition—comparison of ticagrelor with thienopyridines. Br J Pharmacol 173 (2016), 1163–1178.
25. 25 Bonello, L., Laine, M., Kipson, N., et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63 (2014), 872–877.